Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS

McCue, Bette A.; Cason, M.M.; Curtis, Michael A.; Faulkner, Robert; Dahlin, David C.

doi:10.1016/s0731-7085(01)00644-6

Cited by 16 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Techniques such as gas chromatography-mass spectrometry, resonant electron capture mass spectrometry, and electrospray HPLC can be adopted today to refine the classical and mostly abandoned investigation of lipid metabolism in tumors [Kasumov et al, 2002;McCue et al, 2002]. Deuterized precursor of fatty acid may be utilized using resonant electron capture mass spectrometry [Lin and Salem, 2002;Voinov et al, 2002] to trace the fate of fatty acids synthesized by FAS in human prostate cancer cells and in animal models of prostate cancer such as the TRAMP and MPAKT models [Kaplan-Lefko et al, 2003;Majumder et al, 2003].…”

Section: Models and Techniques To Explore The Role Of Fas In Prostatementioning

confidence: 99%

Fatty acid synthase: A metabolic oncogene in prostate cancer?

Migita

Tang

et al. 2003

J of Cellular Biochemistry

259

201

View full text Add to dashboard Cite

In 1920, Warburg suggested that tumors consistently rely on anaerobic pathways to convert glucose to ATP even in the presence of abundant oxygen [Warberg, 1956] despite the fact that it is less efficient for energy supply than aerobic glycolysis. The reasons for this remain obscure to date. More often than not, the microenvironment of solid tumors contains regions of poor oxygenation and high acidity. In this context hypoxia can act in an epigenetic fashion, inducing changes in gene expression and in metabolism for survival. It is reasonable to assume that only the tumor cells capable of developing an unusual tolerance to limiting oxygen availability and to the acidosis resulting from excessive lactate production, can survive. In addition to the striking changes that occur in glucose metabolism, studies in human cancer patients suggest that there is often also an increase in free fatty acid turnover, oxidation and clearance [Legaspi et al., 1987; Hyltander et al., 1991]. For instance, a lipid mobilizing factor produced by tumor cells appears to be responsible for the increase in whole body fatty acid oxidation [Russell and Tisdale, 2002]. Fatty acids synthesis in tumor tissues also occurs at very high rates, as first demonstrated more than half a century ago [Medes et al., 1953]. Importantly, (14)C glucose studies have shown that in tumor cells almost all fatty acids derive from de novo synthesis despite adequate nutritional supply [Sabine and Abraham, 1967; Ookhtens et al., 1984; Weiss et al., 1986]. In addition, tumors overexpressing fatty acid synthase (FAS), the enzyme responsible for de novo synthesis of fatty acids, display aggressive biologic behavior compared to those tumors with normal FAS levels, suggesting that FAS overexpression confers a selective growth advantage. Here, we will review the roles that FAS plays in important cellular processes such as apoptosis and proliferation. In addition, speculations on the putative role of FAS in the altered metabolic pathways of prostate cancer cells will be explored. Because of the frequent overexpression of this enzyme prostate cancer, FAS constitutes a therapeutic target in this disease.

show abstract

Section: Models and Techniques To Explore The Role Of Fas In Prostatementioning

confidence: 99%

Fatty acid synthase: A metabolic oncogene in prostate cancer?

Migita

Tang

et al. 2003

J of Cellular Biochemistry

259

201

View full text Add to dashboard Cite

show abstract

“…After bilateral administration, travoprost free acid reaches a maximum plasma level of 10 −10 M, which remains constant after 7 days of administration (no accumulation). 21 Plasma half-life of travoprost acid is approximately 45 minutes and less than 2% of topical ocular dose is excreted in the urine within 4 hours from administration.…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Quaranta¹,

Riva²,

Katsanos³

et al. 2015

OPTH

View full text Add to dashboard Cite

Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

show abstract

“…Recently, HPLC-tandem mass spectrometry (HPLC/MS/ MS) [36][37][38][39][40] has become one of the major tools for biomedical analysis due to the fact tandem mass spectrometry (MS/MS) can provides not only extraordinarily high sensitivity and selectivity but also low background noise caused by the biological matrices. The purpose of this study is to develop a fast and sensitive liquid chromatographic-tandem mass spectrometric method for determination of lorazepam in plasma samples.…”

Section: Introductionmentioning

confidence: 99%